AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson'"'"'s disease (including idiopathic and inherited forms of Parkinson'"'"'s disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer'"'"'s disease (LBV), Combined Alzheimer'"'"'s and Parkinson disease, pure autonomic failure and multiple system atrophy.
6 Citations
70 Claims
-
1-56. -56. (canceled)
-
57. A method of treating Parkinson'"'"'s disease or other synucleinopathy in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody which specifically binds to human alpha-synuclein and comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 1, 35, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs;
4, 5, and 6, respectively. - View Dependent Claims (58, 59, 60, 61, 62, 63, 64)
- 1, 35, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs;
-
65. A method of treating Parkinson'"'"'s disease in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody which specifically binds to human alpha-synuclein and comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 1, 35, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs;
4, 5, and 6, respectively. - View Dependent Claims (66, 67, 68, 69, 70)
- 1, 35, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs;
Specification